Methods for Treating Amyotrophic Lateral Sclerosis
OwnerNeil M. Bodie, Renee Bodie +1inventors
InventorsNeil M. Bodie, Renee Bodie, Elliot Altman
Life of this patent
Estimating the term…
Abstract
Polypeptides and other compounds that can bind specifically to the CH2-CH3 cleft of an immunoglobulin molecule, and methods for using such polypeptides and compounds to inhibit Fc-mediated immune complex formation, immune complexed IgG binding to IgG FγR, and immune complexed IgG binding to mC1q (membrane C1q) or soluble C1q. The polypeptides and compounds provided herein can have therapeutic use in treating amyotrophic lateral sclerosis (ALS).
Claims22
A method for inhibiting immune complex formation in a subject, said method comprising administering to said subject a composition comprising a purified polypeptide, said polypeptide comprising the amino acid sequence (Xaa1)n-Cys-Ala-Xaa2-His-Leu-Gly-Glu-Leu-Val-Trp-Cys-Thr-(Xaa3)n (SEQ ID NO:35), wherein Xaa1 is any amino acid, Xaa2 is a Arg, Trp, Tyr or Phe, 5-hydroxytryptophan (5-HTP), Xaa3 is any amino acid, and n is 0, 1, 2, 3, 4, or 5.
A purified polypeptide, the amino acid sequence of which consists of:
- (Xaa1)n-Cys-Ala-Xaa2-His-Leu-Gly-Glu-Leu-Val-Trp-Cys-Thr-(Xaa3)n (SEQ ID NO:35), wherein Xaa1 is any amino acid, Xaa2 is Arg, Trp, 5-HTP, Tyr, or Phe, Xaa3 is any amino acid, and n is 0, 1, 2, 3, 4, or 5.
A method of designing a ligand having specific binding affinity for the CH2-CH3 cleft of an immunoglobulin molecule having bound antigen, said method comprising designing a ligand that has hydrophobic packing or intermolecular interactions with IgG Fc amino acid residues Met-252, Ile-253, Ser-254, His-435, and Tyr-436, wherein said ligand binds specifically to IgG Fc amino acid residues Met-252, Ile-253, Ser-254, His-435, and Tyr-436, and wherein said ligand prevents the binding of other molecules to IgG Fc amino acid residues Met-252, Ile-253, Ser-254, His-435, and Tyr-436.
Dependencies are inferred from the claim text.